Comparing BMS-986365 with standard therapies for advanced prostate cancer
Official title: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
Run by Celgene · NCT06764485 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new drug called BMS-986365 to see if it works better than standard treatments for men with advanced prostate cancer that has spread and is resistant to hormone therapy.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 960 (estimated) |
| Sponsor | Celgene Industry-sponsored |
| Drugs / interventions | Prednisone |
| Locations | 282 sites (Birmingham, Alabama and 281 other locations) |
| Trial ID | NCT06764485 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men with confirmed metastatic castration-resistant prostate cancer who have previously received androgen receptor pathway inhibitors.
✕Probably not a fit
Patients with significant cardiac disease, brain or liver metastases, or those with severe symptoms from prostate cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the efficacy and safety of BMS-986365 compared to the investigator's choice of therapy in patients with metastatic castration-resistant prostate cancer. Participants will be randomly assigned to receive either BMS-986365 at one of two dose levels or standard treatments such as Docetaxel with Prednisone, Abiraterone with Prednisone, or Enzalutamide. The primary endpoint is to assess radiographic progression-free survival (rPFS) between the treatment groups. The study is divided into two parts, with randomization occurring at different stages to ensure robust data collection.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for patients with advanced prostate cancer.
How similar studies have gone: Other studies have shown promising results with similar approaches in targeting advanced prostate cancer, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features. * Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computed tomography/magnetic resonance imaging (CT/MRI). * Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory - Short Form (BPI-SF) that must be \< 4. * Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide). Exclusion Criteria * Participants must not have impaired cardiac function or clinically significant cardiac disease. * Participants must not have any brain metastasis. * Participants must not have any liver metastasis. * Participants with superscan on technetium-99m (Tc-99m) radionuclide bone scans. * Other protocol-defined Inclusion/Exclusion criteria apply.
Where it's running
-
Central Alabama Research
Birmingham, Alabama, United States Recruiting -
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States Recruiting -
Moores Cancer Center
La Jolla, California, United States Recruiting -
Cancer and Blood Specialty Clinic
Los Alamitos, California, United States Recruiting -
California Pacific Medical Center
San Francisco, California, United States Recruiting -
San Francisco VA Health Care System
San Francisco, California, United States Recruiting
Show 44 more locations
-
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, United States Recruiting -
Rocky Mountain Cancer Centers, LLP
Denver, Colorado, United States Recruiting -
Colorado Clinical Research
Lakewood, Colorado, United States Recruiting -
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States Recruiting -
Lakeland Regional Cancer Center
Lakeland, Florida, United States Recruiting -
Northwestern Memorial Hospital
Chicago, Illinois, United States Recruiting -
The University of Kansas Cancer Center - Westwood
Westwood, Kansas, United States Recruiting -
Wichita Urology Group
Wichita, Kansas, United States Recruiting -
Chesapeake Urology
Baltimore, Maryland, United States Recruiting -
Johns Hopkins Hospital
Baltimore, Maryland, United States Recruiting -
James M Stockman Cancer Institute
Frederick, Maryland, United States Recruiting -
Thomas Jefferson University, Kennedy Health Alliance
Sewell, New Jersey, United States Recruiting -
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States Recruiting -
New Mexico Oncology Hematology Consultants Ltd.
Albuquerque, New Mexico, United States Recruiting -
Roswell Park Cancer Institute
Buffalo, New York, United States Recruiting -
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York, United States Recruiting -
Laura and Isaac Perlmutter Cancer Center
New York, New York, United States Recruiting -
Icahn School of Medicine at Mount Sinai
New York, New York, United States Recruiting -
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting -
Associated Medical Professionals - Urology
Syracuse, New York, United States Recruiting -
Providence Portland Medical Center
Portland, Oregon, United States Recruiting -
Providence St. Vincent Medical Center
Portland, Oregon, United States Recruiting -
Philadelphia Veterans Affairs Medical Center
Philadelphia, Pennsylvania, United States Recruiting -
Thomas Jefferson University - Clinical Research Institute
Philadelphia, Pennsylvania, United States Recruiting -
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States Recruiting -
Asplundh Cancer Pavilion
Willow Grove, Pennsylvania, United States Recruiting -
Hollings Cancer Center
Charleston, South Carolina, United States Recruiting -
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina, United States Recruiting -
Tennessee Oncology
Nashville, Tennessee, United States Recruiting -
Texas Oncology - Central/South Texas
Austin, Texas, United States Recruiting -
Urology Austin, PLLC
Austin, Texas, United States Recruiting -
University of Texas MD Anderson Cancer Center
Houston, Texas, United States Recruiting -
Intermountain Medical Center
Murray, Utah, United States Recruiting -
University of Virginia Cancer Center
Charlottesville, Virginia, United States Recruiting -
Northwest Cancer Specialists, P.C.
Vancouver, Washington, United States Recruiting -
Medical College of Wisconsin
Milwaukee, Wisconsin, United States Recruiting -
Hospital Británico de Buenos Aires
Caba, Buenos Aires, Argentina Recruiting -
Instituto Alexander Fleming
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina Recruiting -
Hospital Italiano de Buenos Aires
Abb, Buenos Aires F.D., Argentina Recruiting -
Hospital Italiano de Córdoba
Córdoba, Córdoba Province, Argentina Recruiting -
Clinica Viedma S. A
Viedma, R, Argentina Recruiting -
Asociación de Beneficencia Hospital Sirio Libanés
Buenos Aires, Argentina Recruiting -
Hospital Privado Universitario de Córdoba
Córdoba, Argentina Recruiting -
GenesisCare - Campbelltown
Campbelltown, New South Wales, Australia Recruiting
+232 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
JUR-003 in adults with advanced prostate cancer
This first-in-human study tests JUR-003 to see if it is safe and tolerable and to get an early sense of activity in adults with metastatic or advanced prostate cancer.
-
SRT-017 radioligand therapy in PSMA-positive metastatic castration-resistant prostate cancer
This study tests SRT-017 given by IV infusion to men with PSMA-positive metastatic castration-resistant prostate cancer to see if it is safe and tolerable and to gather early signals of anti-tumor activity.
-
Rinzimetostat plus darolutamide in metastatic castration-resistant prostate cancer after abiraterone failure
This study tests whether adding rinzimetostat to darolutamide helps people with metastatic castration-resistant prostate cancer who previously took abiraterone.
-
FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer
This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.
-
Docetaxel and SX-682 in head and neck cancers and prostate cancer
This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.
-
Dual-target PSMA/PSCA CAR-NK Therapy in Advanced Prostate Cancer
This trial tests ETB-DualNK-01, a dual-target CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer to see if it is safe and shows early signs of activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.